drug developer news from FierceBiotech
News
Daiichi Sankyo acquires Ranbaxy in $4.6B deal
Ranbaxy's drive to become a research-based drug developer and major manufacturer has led it straight into the Read more...
BrainCells launches IIa trial after $50M VC round
San Diego-based BrainCells is moving its lead program into a Phase IIa trial after boosting its second venture round with a second tranche. The new money brings its second round to $50 million. Read more...
Pfizer, Avant ink $440M cancer vax deal
Avant Immunotherapeutics is pocketing a $40 million upfront fee and a $10 million equity stake from Pfizer in exchange for the worldwide rights to Avant's experimental brain cancer vaccine. And Read more...
Feds ok Iomai Phase II adjuvant patch study
Health and Human Services is giving Iomai the green light to do a mid-stage dose ranging study of its adjuvant patch for bird flu vaccine. HHS provided a $128 million contract backing Iomai's effort Read more...
Market volatility spurs M&A talks at UK biotechs
Up until last week, Renovo was the poster child for success in the UK's biotech industry. Then after one of its therapies failed Read more...
Panacos surges on HIV response data
Shares of Panacos shot up yesterday when the drug developer reported that it discovered factors that predict response to bevirimat, its lead HIV maturation inhibitor. Patients who had few mutations Read more...
Vernalis may be in play after dramatic reorg
The UK's Vernalis saw its shares shoot up after the drug developer announced a dramatic restructuring that will eliminate more than half of its work force and put significant parts of its business up Read more...
Rumor Mill: Sanofi to buy Oxford BioMedica
Rumors are swirling that Sanofi-Aventis may be making a bid for Oxford BioMedica, a U.K.-based developer of gene-based medicines. Oxford's shares have surged in response to a report published in The Read more...
Lilly sees pipeline hope in MS drug
An article in the Indianapolis Star details Lilly's development program for MBP9289, a multiple sclerosis drug offering hope to both patients and a drug developer that hasn't launched a new drug for Read more...
Neurogen cuts 70 jobs in restructuring
Neurogen is slashing 70 jobs in a restructuring that will focus company assets around its clinical programs. The drug developer is focused on insomnia, Parkinson's disease, restless legs syndrome and Read more...
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends